Jump to any asset
849 assets, updated daily
As of September 27, 2026, Recursion Pharmaceuticals, Inc. (RXRX) trades at $3.740. CleaRank Financial AI rates it Hold with a fair value of $7.000, 87.2% above the current price. Wall Street's consensus target is $7.000 across 7 analysts. RSI at 52 is in neutral territory, and the price is above its 50-day average of $3.315.
Recursion Pharmaceuticals, Inc. (RXRX)
Recursion Pharmaceuticals, Inc. NASDAQ
$3.74
-0.1500 (-3.86%)
At close: Sep 25, 4:00 PM EDT
AI Analyst Consensus
59 / 100
Recursion Pharmaceuticals (RXRX) is currently trading at $3.74, above its 50-day and 200-day moving averages ($3.32 and $3.59), indicating a neutral momentum. The company operates in the Biotechnology sector within Healthcare, a space that has seen median revenue growth of 8.1%. RXRX's own revenue growth has been negative at -60.1%, contrasting sharply with the sector average and raising concerns about its current business trajectory despite a significant increase in revenue estimates for the current quarter. Wall Street analysts maintain a 'Hold' consensus with a median price target of $7.00, suggesting an 87.2% upside from the current price. However, the company's financial health shows persistent losses, with a negative EPS of -1.00 and a substantial operating margin of -1,759.69%. While the company has a low debt-to-equity ratio of 0.07, its profit margin is a slim 4.45%, and its return on equity is a negative -56.58%. Insider activity shows a 'Moderate Sell Signal' with over $13.2 million in sales versus no reported purchases, adding a layer of caution.
RXRX Price Analysis
Market Metrics
Open
$3.89
Day Range
$3.70 to $3.90
Prev Close
$3.89
Volume
10.43M
52-Week Range
$2.77 to $7.18
Market Cap
$2.01B
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
On price-to-sales, the yardstick used here in place of P/E, RXRX trades at 36.56x, far above the sector average of 3.70x.
RXRX Financial Performance
Revenue vs. Earnings
Annual
Quarterly
Earnings Reality Check
Analysis: In the last 3 quarters, RXRX beat estimates 2 times. However, the stock fell 1 times the next day. This suggests positive news is often "priced in" or investors are selling the news.
RXRX Analysis
Company's Health
3/5
AI Technical Analysis
Recursion Pharmaceuticals is currently trading above its 50-day and 200-day moving averages ($3.32 and $3.59), with its price also positioned above the 20-day Exponential Moving Average, suggesting a neutral to slightly positive short-term trend. The Relative Strength Index (RSI) is at 52.21, indicating neutral momentum, neither overbought nor oversold. The MACD is slightly positive at 0.137, hinting at a potential shift in momentum. Key support levels are indicated by the 50-day SMA at $3.32 and the 200-day SMA at $3.59, while the 20-day EMA sits at $3.57. The current price of $3.74 is testing resistance near its recent highs. Volume has been below average recently, down 57.9% from its average, which could suggest a lack of conviction behind the current price action. The overall chart structure suggests a period of consolidation as the stock attempts to build a base above its key moving averages.
ProTips
- Insider selling totaling over $13.2 million suggests caution, despite the 'Hold' consensus from Wall Street analysts.
- The stock is trading above key moving averages (50-day and 200-day SMA), indicating neutral to positive short-term momentum, but volume is below average.
- Given the company's ongoing losses and high valuation multiples, investors should consider position sizing carefully and monitor revenue growth trends closely.
Key Catalysts
Bullish
Strong Revenue Growth Estimates for Current Quarter
Analysts project revenue growth of +152.00% year-over-year for the current quarter, indicating strong potential for top-line expansion.
Source: Wall Street EstimatesBullish
Upside Potential to Median Analyst Price Target
The median analyst price target of $7.00 represents an 87.2% upside from the current stock price, suggesting potential for significant price appreciation.
Source: Wall Street EstimatesBearish
Moderate Insider Selling Signal
Insiders have sold over $13.2 million worth of stock with no reported purchases, indicating a 'Moderate Sell Signal' and potential lack of confidence.
Source: Insider TransactionsBearish
Persistent Net Losses and Negative EPS
The company continues to report net losses, with a negative EPS of -1.00 for the latest reported period, raising concerns about long-term profitability.
Source: Company FinancialsMarket Outlook
The base case outlook for Recursion Pharmaceuticals anticipates a potential recovery driven by projected revenue growth and analyst price targets suggesting significant upside. The median analyst target price of $7.00 implies an 87.2% increase from the current price, reflecting optimism about the company's long-term potential in the biotechnology space. Analysts forecast revenue growth of 35.3% for the current year, signaling a potential shift towards commercialization and increased sales. However, the path forward is fraught with risk. The company's persistent losses, negative EPS, and moderate insider selling present significant headwinds. A key factor to watch will be the company's ability to translate projected revenue growth into profitability and manage its cash burn effectively. Failure to do so, or a continuation of insider selling, could lead to a downside scenario, with Monte Carlo simulations suggesting a potential price drop to $0.58 by 2030.
Key Statistics
| Market Cap | 2.01B |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -1.00 |
| Dividend Yield | 0.00% |
| 52 Week High | 7.18 |
| 52 Week Low | 2.77 |
Recursion Pharmaceuticals exhibits a high price-to-sales ratio of 36.56, significantly above the sector median of 3.7, indicating that the stock is richly valued relative to its current sales. The company's negative EPS of -1.00 means its P/E ratio is not applicable, and its profit margin of 4.45% is considerably lower than the sector median of 6.9%. Despite these valuation concerns, analysts project substantial revenue growth for the current quarter, with estimates showing a +152.00% year-over-year increase, though the next quarter's estimate shows a significant decline. The company's balance sheet appears relatively strong with a low debt-to-equity ratio of 0.07, suggesting minimal financial leverage. However, its return on equity is significantly negative at -56.58%, highlighting ongoing profitability challenges. The current valuation metrics suggest that the market is pricing in significant future growth, which is not yet reflected in current profitability or sales trends.
Earnings & Growth Analysis
Recursion Pharmaceuticals reported a loss of -$0.25 per share for the quarter ending June 2026, missing the analyst estimate of -$0.23 by 8.7%, and the stock saw a modest 0.32% increase following the announcement. This follows a pattern of consistent losses, with the company missing estimates in the prior quarter as well, though it has shown some positive surprise percentages in earlier periods. Revenue for the current quarter is estimated to grow significantly by 152.00% year-over-year, indicating a potential turnaround in top-line performance, but forward-looking estimates for the next quarter show a sharp contraction.
Key Risks
Recursion Pharmaceuticals faces significant risks, including its ongoing unprofitability, evidenced by a negative EPS and a substantial operating margin loss, which contrasts with its high price-to-sales ratio. Moderate insider selling, with over $13.2 million in sales versus no reported purchases, signals a lack of confidence from management. Also, the company's revenue growth has been sharply negative at -60.1%, raising concerns about its ability to achieve sustainable growth despite optimistic near-term revenue estimates.
Technical Indicators
| RSI (14) | 52.21 |
|---|---|
| MACD | 0.14 |
| SMA 50 | 3.32 |
| SMA 200 | 3.59 |
RSI
Neutral
SMA Cross
Bearish
Price vs SMA
Bullish
MACD
Bullish
Moving averages show a lagging Death Cross (50-day: $3.315, 200-day: $3.586), price action is firmly bullish above key moving averages.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.54
Moderate correlation
Nasdaq 100 (QQQ)
+0.54
Moderate correlation
Bitcoin (BTC)
+0.44
Moderate correlation
Gold (XAU)
+0.18
Weak correlation
Check Custom Correlation
How does any other asset move with RXRX? One year of daily closes, Pearson correlation.
Try
RXRX Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies pick an entry style
Conservative
$3.703
Slight discount to current
Wait for small dip
Aggressive
$3.740
At current price
Enter now if confident
Risk Management
STOP LOSS
$3.398
MAX LOSS
-8.2%
Volatility-Adjusted Stop Loss
Calculated based on RSI (52.2) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$3.814
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$3.888
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$3.999
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
RXRX is classified as a high-volatility asset (Daily Vol: 5.49%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 27, 2026.Growth of $10,000
A $10,000 investment in RXRX in April 2021 would be worth about $1,195 today, compared with about $18,486 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in RXRX today could grow to about $2,370 by 2036 in the base case, with a bull case near $17,979 and a bear case around $312. Projections are statistical simulations, not guarantees.
RXRX Stock Price Prediction: 2030
CleaRank's simulation projects a price near $2.10 for RXRX by 2030 in the base case, from $3.74 today (0.6x over 4 years). The downside path ends near $0.5837. These are outcomes of a Monte Carlo simulation run on RXRX's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $1.71 | $3.24 | $6.15 |
| 2028 | $1.13 | $2.80 | $6.94 |
| 2029 | $0.8003 | $2.43 | $7.37 |
| 2030 | $0.5837 | $2.10 | $7.57 |
| 2031 | $0.4344 | $1.82 | $7.63 |
| 2032 | $0.3281 | $1.58 | $7.57 |
| 2033 | $0.2505 | $1.37 | $7.44 |
| 2034 | $0.193 | $1.18 | $7.24 |
| 2035 | $0.1497 | $1.02 | $7.00 |
| 2036 | $0.1168 | $0.8863 | $6.72 |
Method: 10,000 simulated price paths using RXRX's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
RXRX Insider Trading Analysis
Bought
None
No open-market buys
Sold
$13.2M
39 Transactions
Insiders
12
Active Traders
Avg Transaction
$338.7K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jan 14, 2022 | GIBSON CHRISTOPHER
Chief Executive Officer
|
Sell | 341.0K | $4.7M |
| Aug 11, 2025 | GIBSON CHRISTOPHER
Chief Executive Officer
|
Sell | 618.2K | $3.3M |
| Mar 7, 2022 | GIBSON CHRISTOPHER
Chief Executive Officer
|
Sell | 300.0K | $2.2M |
| Mar 15, 2022 | GIBSON CHRISTOPHER
Chief Executive Officer
|
Sell | 336.2K | $2.2M |
| Jul 13, 2023 | BURRELL TERRY-ANN
Director
|
Sell | 117.0K | $1.4M |
| Apr 4, 2024 | GIBSON CHRISTOPHER C
Chief Executive Officer
|
Sell | 130.0K | $1.2M |
| Feb 22, 2022 | GIBSON CHRISTOPHER
Chief Executive Officer
|
Sell | 100.0K | $1.0M |
| Dec 2, 2025 | BORGESON BLAKE CHARLES
Director
|
Sell | 220.0K | $961.4K |
| Jan 6, 2026 | BORGESON BLAKE CHARLES
Director
|
Sell | 220.0K | $959.2K |
| Feb 3, 2026 | BORGESON BLAKE CHARLES
Director
|
Sell | 220.0K | $924.0K |
Page 1 of 1
Frequently Asked Questions
What is Recursion Pharmaceuticals' stock price forecast for 2030?
Based on Monte Carlo simulations, Recursion Pharmaceuticals' stock price is projected to be $2.10 in 2030 under a base case scenario. The downside projection is $0.58, while the upside projection reaches $7.57. These figures represent statistical outcomes and are not definitive price targets.
Is Recursion Pharmaceuticals stock a buy right now?
Recursion Pharmaceuticals holds a 'Hold' consensus rating from Wall Street analysts, supported by a median price target of $7.00, which suggests significant upside potential. However, the company's persistent losses and moderate insider selling present considerable risks that temper a strong buy recommendation.
What are the key technical levels for Recursion Pharmaceuticals stock?
Recursion Pharmaceuticals is currently trading above its 50-day SMA ($3.32) and 200-day SMA ($3.59), indicating support at these levels. The RSI is neutral at 52.21, suggesting no immediate overbought or oversold conditions.
What is the insider sentiment for Recursion Pharmaceuticals?
Insider sentiment for Recursion Pharmaceuticals is currently a 'Moderate Sell Signal,' with over $13.2 million in sales reported by insiders versus no reported purchases. This indicates a net selling pressure from management.
How does Recursion Pharmaceuticals compare to its sector averages?
Recursion Pharmaceuticals' price-to-sales ratio of 36.56 is significantly higher than the sector median of 3.7. Its negative return on equity of -56.58% also lags behind the sector median of 6.9%, though its debt-to-equity ratio of 0.07 is lower than the sector average.
What are the recent earnings trends for Recursion Pharmaceuticals?
Recursion Pharmaceuticals reported a loss of -$0.25 per share for the quarter ending June 2026, missing analyst estimates. While revenue is projected to grow significantly year-over-year for the current quarter, the company has a history of losses and missed earnings expectations.
What is the outlook for Recursion Pharmaceuticals' revenue growth?
Analysts project substantial revenue growth for Recursion Pharmaceuticals in the current quarter, with estimates indicating a 152.00% year-over-year increase. However, projections for the next quarter show a significant contraction, suggesting potential volatility in top-line performance.